↓ Skip to main content

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
7 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Published in
Journal for Immunotherapy of Cancer, September 2018
DOI 10.1186/s40425-018-0401-3
Pubmed ID
Authors

Guozhu Xie, Tan Cheng, Jie Lin, Lanfang Zhang, Jieling Zheng, Ying Liu, Guobo Xie, Baiyao Wang, Yawei Yuan

Abstract

Current checkpoint immunotherapy has shown potential to control cancer by restoring or activating the immune system. Nevertheless, multiple mechanisms are involved in immunotherapy resistance which limits the clinical benefit of checkpoint inhibitors. An immunosuppressive microenvironment is an important factor mediating the original resistance of tumors to immunotherapy. A previous report by our group has demonstrated that local angiotensin II (AngII) predominantly exists in a tumor hypoxic microenvironment where hypoxic tumour cells produced AngII by a hypoxia-lactate-chymase-dependent mechanism. Here, using 4T1 and CT26 syngeneic mouse tumor models, we found that local AngII in the tumor microenvironment was involved in immune escape of tumour cells and an AngII signaling blockage sensitized tumours to checkpoint immunotherapy. Furthermore, an AngII signaling blockage reversed the tumor immunosuppressive microenvironment, and inhibition of angiotensinogen (AGT, a precursor of AngII) expression strongly triggered an immune-activating cytokine profile in hypoxic mouse cancer cells. More importantly, AGT silencing combined with a checkpoint blockage generated an abscopal effect in resistant tumors. Our study demonstrated an important role of local AngII in the formation of a tumor immunosuppressive microenvironment and its blockage may enhance tumor sensitivity to checkpoint immunotherapy. The combination of an AngII signaling blocker and an immune-checkpoint blockage could be a promising strategy to improve tumors responses to current checkpoint immunotherapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 11%
Researcher 4 11%
Student > Master 4 11%
Student > Bachelor 3 8%
Professor > Associate Professor 2 6%
Other 6 17%
Unknown 13 36%
Readers by discipline Count As %
Medicine and Dentistry 8 22%
Biochemistry, Genetics and Molecular Biology 7 19%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Unspecified 2 6%
Agricultural and Biological Sciences 1 3%
Other 2 6%
Unknown 13 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2020.
All research outputs
#5,482,691
of 25,498,750 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,426
of 3,451 outputs
Outputs of similar age
#98,745
of 348,250 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#22
of 35 outputs
Altmetric has tracked 25,498,750 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,451 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,250 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.